Skip to content

Clinical study of combined esketamine for the prevention of hypotension during anesthesia induction with remimazolam

Clinical study of combined esketamine for the prevention of hypotension during anesthesia induction with remimazolam

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400082181
Enrollment
Unknown
Registered
2024-03-22
Start date
2024-03-25
Completion date
Unknown
Last updated
2024-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesia

Interventions

Esketamine group:Anesthesia was induced by esketamine 0.4mg/kg IV, followed by remimazolam, cis-atracurium, and sufentanil.
Normal saline group:Anesthesia was induced by intravenous injection of the same volume of NS, followed by remimazolam, cis-atracurium, and sufentanil.

Sponsors

The First Affiliated Hospital of Guangxi Medical University Ethical Committee
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-60; 2. ASA1-III; 3. Patients undergoing elective surgery under general anesthesia.

Exclusion criteria

Exclusion criteria: 1. Obesity; 2.Difficult airway; 3.Take analgesics; 4.Severe hypertension; 5. Lung heart illness; 6. Pulmonary hypertension; 7. Cardiac insufficiency; 8. Hyperthyroidism; 9. Epilepsy and psychosis; 10. Allergic to the drug being studied.

Design outcomes

Primary

MeasureTime frame
Incidence of hypotension after anesthesia induction;

Secondary

MeasureTime frame
Vital signs such as blood pressure, heart rate, SpO2, and BIS ;Total doses of vasoactive drugs;Total dose of anesthetic drugs;Time of loss of consciousness;Time of Bis = 60;

Countries

China

Contacts

Public ContactXuehai Guan

The First Affiliated Hospital of Guangxi Medical University

guan_xh@aliyun.com+86 185 8769 7310

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026